Table 4.
Interaction analysis of eGFR and prevalence of kidney adverse events in subgroups based on SU and urine pH values
| Kidney disease outcomes | pH ≤ 5.0 | 5.0 < pH≤ 5.5 | 5.5 < pH < 6.2 | 6.2 ≤ pH ≤ 6.9 | pH > 6.9 | P for interaction |
|---|---|---|---|---|---|---|
| 1 stage CKD | 0.027 | |||||
| SU>480 | 1.88 (1.38~2.55) | 1.04 (0.79~1.38) | 1.04 (0.78~1.38) | reference | 1.20 (0.82~1.77) | |
| SU ≤ 480 | 2.90 (1.85~4.56) | 2.20 (1.48~3.26) | 1.375 (0.92~2.05) | reference | 1.70 (1.06~2.72) | |
| Nephrolithiasis | 0.08 | |||||
| SU>480 | 1.73 (1.20~2.45) | 0.70 (0.49~1.01) | 0.93 (0.66~1.33) | reference | 0.99 (0.61~1.60) | |
| SU ≤ 480 | 2.98 (1.68~5.28) | 1.27 (0.73~2.20) | 0.860 (0.48~1.53) | reference | 1.60 (0.85~3.02) | |
| Microhematuria | 0.173 | |||||
| SU>480 | 1.66 (1.19~2.30) | 1.37 (1.00~1.89) | 1.30 (0.94~1.80) | reference | 1.57 (1.04~2.36) | |
| SU ≤ 480 | 2.94 (1.84~4.72) | 1.47 (0.97~2.22) | 1.32 (0.88~1.99) | reference | 1.50 (0.95~2.39) | |
| Proteinuria | 0.234 | |||||
| SU>480 | 2.49 (1.06~5.82) | 3.91 (1.74~8.78) | 3.34 (1.47~7.59) | reference | 1.53 (0.53~4.44) | |
| SU ≤ 480 | 5.40 (1.53~19.08) | 3.25 (0.93~11.43) | 2.88 (0.82~10.20) | reference | 2.12 (0.52~8.62) |